143 related articles for article (PubMed ID: 28956335)
1. Role of PDE9 in Cognition.
Dorner-Ciossek C; Kroker KS; Rosenbrock H
Adv Neurobiol; 2017; 17():231-254. PubMed ID: 28956335
[TBL] [Abstract][Full Text] [Related]
2. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
3. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice.
da Silva FH; Pereira MN; Franco-Penteado CF; De Nucci G; Antunes E; Claudino MA
Int J Impot Res; 2013; 25(2):69-73. PubMed ID: 23034509
[TBL] [Abstract][Full Text] [Related]
5. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
6. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
[TBL] [Abstract][Full Text] [Related]
7. Gastrodin promotes hippocampal neurogenesis via PDE9-cGMP-PKG pathway in mice following cerebral ischemia.
Xiao H; Jiang Q; Qiu H; Wu K; Ma X; Yang J; Cheng O
Neurochem Int; 2021 Nov; 150():105171. PubMed ID: 34419525
[TBL] [Abstract][Full Text] [Related]
8. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
Vardigan JD; Converso A; Hutson PH; Uslaner JM
J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
[TBL] [Abstract][Full Text] [Related]
9. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
[TBL] [Abstract][Full Text] [Related]
11. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
13. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains.
Reyes-Irisarri E; Markerink-Van Ittersum M; Mengod G; de Vente J
Eur J Neurosci; 2007 Jun; 25(11):3332-8. PubMed ID: 17553001
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
15. The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice.
Liddie S; Anderson KL; Paz A; Itzhak Y
J Psychopharmacol; 2012 Oct; 26(10):1375-82. PubMed ID: 22596207
[TBL] [Abstract][Full Text] [Related]
16. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
18. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.
Wu Y; Wang Q; Jiang MY; Huang YY; Zhu Z; Han C; Tian YJ; Zhang B; Luo HB
J Med Chem; 2021 Jul; 64(13):9537-9549. PubMed ID: 34142552
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
